Top Pharmaceutical Companies in Boston, MA (130)
Who We Are Chewy is where pet parents find everything they need for life with pets, from food to fun to pharmacy. We make pet care easier, more informed, and more joyful through fast, reliable delivery and award-winning 24/7 Customer Care, including access to pet health support when it’s needed. Founded in 2011, Chewy combines the convenience of online shopping with...
Chewy's Top Stability & Growth Strengths
Customer Loyalty & Retention: Autoship accounts for the vast majority of sales (over four-fifths) and is growing faster than total revenue, indicating a sticky, recurring base and higher retention. Evidence includes Autoship representing ~83% of FY2025 net sales and ~84.6% in Q2 FY2026 with high single‑digit to double‑digit growth.
Profitability: Operating metrics show expanding earnings power, with adjusted EBITDA up materially and margins improving alongside strong free cash flow. Observations include FY2025 adjusted EBITDA growth of ~26% with margin expansion and additional year‑over‑year gains reported in 1H FY2026.
Strong Market Position & Advantage: Chewy is characterized as the largest U.S. pet e‑tailer and a leading online pet‑supplies platform by GMV and digital presence, underpinning durable scale advantages. Multiple summaries highlight leadership in online pet retail, substantial Autoship penetration, and strong digital search share versus specialty peers.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability & Growth Strengths
Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.
Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.
Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.
Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.
Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.
AstraZeneca is a global, science-led, patient-focused biopharmaceutical company committed to excellence in the research, development, and commercialization of prescription medicines. With approximately 90,000 employees across 85 countries, the company aims to unlock the power of science to deliver innovative medicines that transform patient outcomes and improve healthcare for people, society, and the planet worldwide.
Quantori is the end-to-end data, technology, and digital services partner of choice for leading biopharma and healthcare organizations across the globe. We develop cutting-edge data and technology systems, applications, and infrastructures for biotech, pharmaceutical, and healthcare companies to accelerate drug discovery and improve patient outcomes. Our innovative approach harnesses the power of data engineering and informatics, machine learning, emerging technologies, and...
Konovo is a global healthcare intelligence company on a mission to transform healthcare research by connecting insights across the life science ecosystem. Originally launched in 2019 as Apollo Intelligence, Konovo was born out of the combined capabilities of three industry-leading healthcare research firms: InCrowd, Survey Healthcare Global (SHG), and GlocalMind. Konovo’s 300+ employees support top global pharmaceutical and healthcare brands, market...
The National MS Society is a non-profit organization dedicated to curing multiple sclerosis while empowering people affected by the disease to live their best lives through research, education, and support.
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on...
BioPharma Consulting JAD Group provides a complete portfolio of technical support and solutions for the FDA regulated industry. We deliver solutions with a flexible cost effective approach to meet your company’s needs. BPC JAD group is a company created to help our customers bridge the gap between their business strategy and results. Our mission is to help our clients succeed by...
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies,...
Merck's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck holds a clear leadership position, anchored by Keytruda—the world’s top‑selling cancer medicine at $31.7B in 2025—and strong standings in vaccines and overall scale among global pharmas. Animal health also ranks among top players, reinforcing breadth across key healthcare markets.
Innovation-Driven Growth: A broad late‑stage pipeline and scientific presence (100+ ASCO 2026 abstracts across 25+ tumor types) span oncology, vaccines, infectious disease, and cardiometabolic areas. Ongoing label expansions and new formats like subcutaneous Keytruda (including U.S. Keytruda Qlex) are adding growth vectors.
Diversified Revenue Streams: Sales draw from oncology, vaccines (e.g., Gardasil over $10.7B in 2025), hospital acute care, and a growing animal health segment. Newer launches and alliances (e.g., Winrevair, IDVYNSO, and partnered oncology assets) are contributing to mix.
The AMR Action Fund is a groundbreaking VC fund that enables breakthroughs in the development of antibiotics, anti-fungals, and other antimicrobials. We invest in companies developing innovative treatments for priority drug-resistant pathogens and advocate for market reforms and policy solutions to change how society values these lifesaving drugs
Kailera is an advanced clinical-stage biotechnology company focused on obesity care. It is developing a diversified pipeline of GLP-1 therapies and other obesity-management medications intended to provide treatment options for people living with obesity across their treatment journeys. The company’s team has experience developing and commercializing therapies for metabolic diseases, and its clinical-stage candidates use multiple GLP-1 mechanisms and routes...
Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. Invivyd’s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The...
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health and change how brain disorders are thought about and treated. Our mission is to pioneer solutions with the potential to deliver life-changing...
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical...
Parexel's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests Parexel is consistently viewed as a top-tier, full-service CRO, reinforced by repeated industry awards and strong site collaboration recognition. These signals indicate competitive strength in winning and delivering complex global programs.
Strategic Partnerships: Feedback suggests multi-year collaborations to embed advanced analytics and AI (e.g., Palantir and other AI initiatives) are intended to improve trial efficiency and differentiation. Such partnerships underscore continued investment in modernization and execution.
Market Expansion: Feedback suggests the company opened a new global headquarters in Raleigh and continues to reference a 20,000+ to 24,000+ global workforce, indicating operational scaling. Physical expansion and ongoing hiring activity support broader delivery capacity across regions.
Kelonia is pioneering a new wave of genetic medicines using its next generation gene delivery platform. The company’s simple and elegant cutting-edge in vivo gene delivery technology uses a few potent lentiviral vector-like particles to precisely and efficiently deliver in vivo genetic cargo to the desired target tissue, and only that tissue, every time. With an initial focus on developing...
SHYFT Analytics is an industry leader in cloud data management and mobile analytics for the global life sciences industry. SHYFT is used by pharmaceutical, biotech, medical device and other healthcare leaders from around the globe and across thousands of users. With over 10 years innovating in life sciences, SHYFT’s industry cloud platform is leading the transformation in healthcare and helping...
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader medicines for serious diseases, including oncology, autoimmune, inflammatory, cardiovascular, and cardiometabolic conditions. Its QuEEN platform combines proprietary molecular glue libraries with proteomics, structural biology, computational chemistry, and AI/machine learning to discover and develop treatments aimed at disease-driving proteins and pathways long considered undruggable across multiple therapeutic...
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with a Research & Development innovation engine that aims to discover, develop and ultimately deliver impactful medicines to patients. Our programs span discovery-stage to late-stage development and cover a range of high-value indications in rare diseases and immuno-oncology. We are led by a management team with extensive R&D experience, providing direct guidance...
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie...
